Cell Therapy Manufacturing Strategies: Autologous vs. Allogeneic (Individual)

There have been tremendous advancements and breakthroughs in cell therapy treatments. Autologous treatments are extremely effective personalized therapies, but have significant medical, cost and commercialization limitations. Allogeneic treatments provide us with an opportunity to expand and extend access to personalized therapies to patients in need, but face efficacy, safety, and process hurdles. While related, the differences are stark, forcing your company to make unique and critical process and business decisions to ensure your company implements the best technologies to execute the most effective autologous and/or allogeneic cell therapy manufacturing strategy.

Register for Multiple EBP Events

Network, interact and share ideas with fellow bioprocessing leaders and decision-makers and gain access to applicable ideas on how to improve and accelerate your bioprocess. Access to on-demand event presentations, expert podcasts, event eBooks, and more.